SCHEDULE: Lantern Pharma Stakeholder Discloses 7.6% Ownership
Beneficial Ownership Filing
Thomas A. Satterfield, Jr. has reported beneficial ownership of 975,000 shares, representing 7.6% of Lantern Pharma Inc.'s common stock.
Summary
- Thomas A. Satterfield, Jr. has filed an amended Schedule 13G, reporting beneficial ownership of 975,000 shares of Lantern Pharma Inc. common stock.
- This holding represents 7.6% of the total outstanding shares as of May 12, 2026, adjusted for a subsequent share issuance.
- The filing details various entities and individuals through which Mr. Satterfield exercises voting and dispositive power over these shares, including his spouse, a controlled corporation, and investment funds where he holds significant interests.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily a disclosure of existing ownership rather than new strategic information or financial performance.
Positives
- Significant beneficial ownership stake of 7.6% reported by a key stakeholder.
- Clear disclosure of shareholdings and control mechanisms through various entities.
Future Outlook
The filing does not contain forward-looking statements or guidance.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are standard disclosures for significant institutional or individual investors acquiring more than 5% of a company's stock, indicating a notable stake in Lantern Pharma.
Related Party Transactions
- 25,000 shares held jointly with Rebecca S. Satterfield (spouse).
- 100,000 shares held by Tomsat Investment & Trading Co., Inc. (controlled by Mr. Satterfield).
- 500,000 shares held by Caldwell Mill Opportunity Fund, LLC (managed by an entity with 50% ownership by Mr. Satterfield).
- 250,000 shares held by A.G. Family L.P. (managed by a general partner controlled by Mr. Satterfield).
- Limited power of attorney for voting and disposition of 5,000 shares held by Rebecca S. Satterfield.
Stakeholder Impact
- Shareholders: The disclosure confirms a significant ownership stake, which could influence future corporate actions or governance discussions.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Fiscal quarter end for which outstanding shares were reported. |
| 05/12/2026 | Date of issuer's reported outstanding shares. |
| 05/14/2026 | Date of issuer's Form 8-K reporting additional share issuance. |
| 06/30/2026 | Date of event requiring filing of this statement. |
| 07/23/2026 | Date of signature on the Schedule 13G filing. |
Keywords
Lantern Pharma, Schedule 13G, Beneficial Ownership, Shareholder, SEC Filing, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.